Gilead at #IAS25 (Credit: Kyle LaHucik for Endpoints News)
July 14, 2025 09:52 AM EDT
R&D
Pharma

WHO adds Gilead­'s twice-year­ly in­jec­tion to glob­al PrEP guide­lines

Kyle LaHucik

Biotech Correspondent

KI­GALI, RWAN­DA — Weeks af­ter the FDA’s wa­ter­shed ap­proval of Gilead’s twice-year­ly HIV pre­ven­tion in­jec­tion, the World Health Or­ga­ni­za­tion rec­om­mend­ed the prod­uct …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Take­da’s first-in-class nar­colep­sy drug suc­ceeds in two reg­is­tra­tional stud­ies

Boehringer, LEO ink deal for IL-36 drug; Bay­er’s Keren­dia gets an­oth­er in­di­ca­tion

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

A service from the Financial Times